The state-of-play and future of platinum drugs

Endocrine-Related Cancer

Volumn 22, Issue 4, 2015, Pages R219-R233

  Apps, Michael G ^a   Choi, Eugene H Y ^a   Wheate, Nial J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cancer; Cisplatin; Drug delivery; Formulation; Functional genomics

Indexed keywords

ANTIBODY; APTAMER; CALIX[N]ARENE; CARBON NANOTUBE; CISPLATIN; CUCURBIT[N]URIL; CYANOCOBALAMIN; CYCLODEXTRIN DERIVATIVE; DENDRIMER; DICYCLOPLATIN; LIPOSOME; MACROCYCLIC COMPOUND; METAL NANOPARTICLE; N CYCLODEXTRIN; PEPTIDE; PHENANTHRIPLATIN; PHOSPHAPLATIN; PLATINUM DERIVATIVE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; POLYMER; PROLINDAC; PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBOPLATIN; PLATINUM COMPLEX;

CLINICAL EVALUATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG TARGETING; FUNCTIONAL GENOMICS; HUMAN; MICELLE; NUTRIENT; OTOTOXICITY; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DRUG DELIVERY SYSTEMS; HUMANS; ORGANOPLATINUM COMPOUNDS;

EID: 84940107831     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-15-0237     Document Type: Review

References (97)

1. Abramkin S, Valiahdi SM, Jakupec MA, Galanski M, Metzler-Nolte N & Keppler BK 2012 Solid-phase synthesis of oxaliplatin-TAT peptide bioconjugates. Dalton Transactions 41 3001-3005. (doi:10.1039/c2dt12024k)
2. Ajima K, Maigne A, Yudasaka M & Iijima S 2006 Optimum hole-opening condition for cisplatin incorporation in single-wall carbon nanohorns and its release. Journal of Physical Chemistry. B 110 19097-19099. (doi:10.1021/jp064915x)
3. Aronov O, Horowitz AT, Gabizon A & Gibson D 2003 Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconjugate Chemistry 14 563-574. (doi:10.1021/bc025642l)
4. Assaf KI & Nau WM 2014 Cucurbiturils: from synthesis to high-affinity binding catalysis. Chemical Society Reviews 44 394-418. (doi:10.1039/C4CS00273C)
5. Bali MS, Buck DP, Coe AJ, Day AI & Collins JG 2006 Cucurbituril binding of trans-[{PtCl(NH3)2}2(μ-NH2(CH2)8NH2)]2+ and the effect on the reaction with cysteine. Dalton Transactions 5337-5344. (doi:10.1039/b609881a)
6. Bhirde AA, Patel V, Gavard J, Zhang G, Sousa AA, Masedunskas A, Leapman RD, Weigert R, Gutkind JS & Rusling JF 2009 Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano 3 307-316. (doi:10.1021/nn800551s)
7. Bose RN, Maurmann L, Mishur RJ, Yasui L, Gupta S, Grayburn WS, Hofstetter H & Salley T 2008 Non-DNA-binding platinum anticancer agents: cytotoxic activities of platinum-phosphato complexes towards human ovaian cancer cells. PNAS 105 18314-18319. (doi:10.1073/pnas.0803094105)
8. Bouchal P, Jarkovsky J, Hrazdilova K, Dvorakova M, Struharova I, Hernychova L, Damborsky J, Sova P & Vojtesek B 2011 The new platinum-based anticancer agent LA-12 induces retinal binding protein 4 in vivo. Proteome Science 9 1-9. (doi:10.1186/1477-5956-9-68)
9. Brown SD, Nativo P, Smith J-A, Stirling D, Edwards PR, Venugopal B, Flint DJ, Plumb JA, Graham D & Wheate NJ 2010 Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. Journal of the American Chemical Society 132 4678-4684.(doi:10.1021/ja908117a)
10. Brown SD, Plumb JA, Johnston BF & Wheate NJ 2012 Folding of dinuclear platinum anticancer complexes within the cavity of para-sulphonatocalix[4]arene. Inorganica Chimica Acta 393 182-186. (doi:10.1016/j.ica.2012.04.033)
11. Cao Z, Tong R,Mishra A, Xu W, Wong GCL, Cheng J &Lu Y 2009 Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angewandte Chemie (International ed. in English) 48 6494-6498. (doi:10.1002/anie.200901452)
12. Chen G, Kumar J, Gregory A & Stenzel MH 2009 Efficient synthesis of dendrimers via a thiol-yne and esterification process and their potential application in the delivery of platinum anti-cancer drugs. Chemical Communications 41 6291-6293. (doi:10.1039/b910340f)
13. Chu JJ, Apps MG & Wheate NJ 2014 Chemical factors affecting cucurbit[n]uril formulation into ocular dosage forms: excipient binding, solubility, corneal permeability and antibiotic encapsulation. Supramolecular Chemistry 26 648-656. (doi:10.1080/10610278.2014.926361)
14. Coleman AW, Jebors S, Cecillon S, Perret P, Garin D, Marti-Battle D & Moulin M 2008 Toxicity and biodistribution of para-sulfonatocalix[4]arene in mice. New Journal of Chemistry 32 780-782.(doi:10.1039/b718962a)
15. Craig GE, Brown SD, Lamprou D, Graham D & Wheate NJ 2012 Cisplatin tethered gold nanoparticles which exhibit enhanced reproducibility, drug loading and stability - a step closer to pharmaceutical approval? Inorganic Chemistry 51 3490-3497. (doi:10.1021/ic202197g)
16. Dasari S & Tchounwou PB 2014 Cisplatin in cancer therapy: molecular mechanisms of action. European Journal of Pharmacology 740 364-378. (doi:10.1016/j.ejphar.2014.07.025)
17. Davis ME & Brewster ME 2004 Cyclodextrin-based pharmaceutics: past, present and future. Nature Reviews. Drug Discovery 3 1023-1035. (doi:10.1038/nrd1576)
18. Davis KJ, Carrall JA, Lai B, Aldrich-Wright JR, Ralph SF & Dillon CT 2012 Does cytotoxicity of metallointercaltors correlate with cellular uptake or DNA affinity? Dalton Transactions 41 9417-9426. (doi:10.1039/c2dt30217a)
19. Descoteaux C, Provencher-Mandeville J, Mathieu I, Perron V, Mandal SK, Asselin E & Berube G 2003 Synthesis of 17b-estradiol platinum(II) complexes: Biological evaluation on breast cancer cell lines. Bioorganic & Medicinal Chemistry Letters 13 3927-3931. (doi:10.1016/j.bmcl.2003.09.011)
20. Dhar S, Gu FX, Langer R, Farokhzad OC & Lippard SJ 2008a Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. PNAS 105 17356-17361. (doi:10.1073/pnas.0809154105)
21. Dhar S, Liu Z, Thomale J, Dai H & Lippard SJ 2008b Targeted single-walled carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. Journal of the American Chemical Society 130 11467-11476. (doi:10.1021/ja803036e)
22. Dykman L & Khlebtsov N 2012 Gold nanoparticles in biomedical applications; recent advances and perspectives. Chemical Society Reviews 41 2256-2282. (doi:10.1039/C1CS15166E)
23. Eliezar J, Scarano W, Boase NRB, Thurecht K & Stenzel MH 2015 In vivo evaluation of folate decorated cross-linked micelles for the delivery of platinum anticancer drugs. Biomacromolecules 16 515-523.(doi:10.1021/bm501558d)
24. Fabbro C, Ali-Boucetta H, Da Ros T, Kostarelos K, Bianco A & Prato M 2012 Targeting carbon nanotubes against cancer. Chemical Communications 48 3911-3926. (doi:10.1039/c2cc17995d)
25. Fang J, Nakamura H & Maeda H 2011 The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Advanced Drug Delivery Reviews 63 136-151. (doi:10.1016/j.addr.2010.04.009)
26. Feazell RP, Nakayama-Ratchford N, Dai H & Lippard SJ 2007 Soluble singlewalled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. Journal of the American Chemical Society 129 8438-8439. (doi:10.1021/ja073231f)
27. Gagnon V, St-Germain M-E, Descoteaux C, Provencher-Mandeville J, Parent S, Mandal SK, Asselin E & Berube G 2004 Biological evaluation of novel estrogen-platinum(II) hybrid molecules on uterine and ovarian cancers - molecular modeling studies. Bioorganic & Medicinal Chemistry 14 5919-5924. (doi:10.1016/j.bmcl.2004.09.015)
28. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castdeo M & Kroemer G 2012 Molecular mechanisms of cisplatin resistance. Oncogene 31 1869-1883. (doi:10.1038/onc.2011.384)
29. Goldoni L, Grugni M, De Munari S, Cassin M & Bernardini R 2010 Cucurbit[7]uril inclusion complexes of platinum(II)-based anticancer drugs: further insight. Chemistry Letters 39 676-677. (doi:10.1246/cl.2010.676)
30. Guo D-S & Liu Y 2014 Supramolecular chemistry of p-sulfonatocalix[n] arenes and its biological applications. Accounts of Chemical Research 47 1925-1934. (doi:10.1021/ar500009g)
31. Harper BW, Krause-Heuer AM, Grant MP, Manohar M, Garbutcheon- Singh KB & Aldrich-Wright JR 2010 Advances in platinum chemotherapeutics. Chemistry 16 7064-7077. (doi:10.1002/chem.201000148)
32. Haxton KJ & Burt HM2008 Hyperbranched polymers for controlled release of cisplatin. Dalton Transactions 43 5872-5875. (doi:10.1039/b809949a)
33. Hilder TA & Hill JM 2007 Modelling the encapsulation of the anticancer drug cisplatin into carbon nanotubes. Nanotechnology 18 275704 (275708pp). (doi:10.1088/0957-4484/18/27/275704)
34. Hoshino T, Misaki M, Yamamoto M, Shimizu H, Ogawa Y & Toguchi H 1995 Receptor-binding, in vitro cytotoxicity, and in vivo distributions of transferrin-bound cis-platinum(II) differing molar ratios,. Journal of Controlled Release 37 75-81. (doi:10.1016/0168-3659(95)00066-H)
35. Isakoff SJ, Mayer EL, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM et al. 2015 TBCRC009: a multicenter phase II clinical trial of platnum monotherapy with biomarker assessment inmetastatic triple-negative breast cancer. Journal of Clinical Oncology 33 1902-1909. (doi:10.1200/JCO.2014.57.6660)
36. Jensen SS, Andersen TL, Davidsen J, Hoyrup P, Shnyder SD, Bibby MC, Gill JH & Jorgensen K 2004 Secretory phospholipase A2 as a tumorspecific trigger for targeted delivery of a novel class of lipsomal prodrug anticancer etherlipids. Molecular Cancer Therapeutics 3 1451-1458.
37. Jeon YJ, Kim S-Y, Ko YH, Sakamoto S, Yamaguchi K & Kim K 2005 Novel molecular drug carrier: encapsulation of oxaliplatin in cucurbit[7]uril and its effects on stability and reactivity of the drug. Organic & Biomolecular Chemistry 3 2122-2125. (doi:10.1039/b504487a)
38. Johnstone TC, Park GY & Lippard SJ 2014 Understanding and improving platinum anticancer drugs - phenanthriplatin. Anticancer Research 34 471-476.
39. de Jonge MJA, Slingerland M, Loos WJ,Wiemer EAC, Burger H, Mathijssen RHJ, Kroep JR, den Hollander MAG, van der Biessen D, Lam M-H et al. 2010 Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. European Journal of Cancer 46 3016-3021. (doi:10.1016/j.ejca.2010.07.015)
40. Kapp T, Dullin A & Gust R 2010 Platinum(II)-dendrimer conjugates: synthesis and investigations on cytotoxicity, cellular distribution, platinum release, DNA and protein binding. Bioconjugate Chemistry 21 328-337. (doi:10.1021/bc900406m)
41. Kauffman GB, Pentimalli R, Doldi S & Hall MD 2010 Michele Peyrone (1813-1883), discoverer of cisplatin. Platinum Metals Review 54 250-256. (doi:10.1595/147106710X534326)
42. Kellinger MW, Park GY, Chong J, Lippard SJ & Wang D 2013 Effect of a monofunctional phenanthriplatin-DNA dduct on RNA polymerase II transcription fidelity and translesion synthesis. Journal of the American Chemical Society 135 13054-13061. (doi:10.1021/ja405475y)
43. Kemp S, Wheate NJ, Buck DP, Nikac M, Collins JG & Aldrich-Wright JR 2007 The effect of ancillary ligand chirality and phenanthroline functional group substitution on the cytotoxicity of platinum(II)-based metallointercalators. Journal of Inorganic Biochemistry 101 1049-1058. (doi:10.1016/j.jinorgbio.2007.04.009)
44. Khalaila I, Allardyce CS, Verma CS & Dyson PJ 2005 A mass spectrometric and molecular modelling study of cisplatin binding to transferrin. Chembiochem 6 1788-1795. (doi:10.1002/cbic.200500067)
45. Kirkpatrick GJ, Plumb JA, Sutcliffe OB, Flint DJ & Wheate NJ 2011 Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin. Journal of Inorganic Biochemistry 105 1115-1122. (doi:10.1016/j.jinorgbio.2011.05.017)
46. Kozubík A, Horváth V, Švihálková-Šindlerová L, Soucek K, Hofmanová J, Sova P, Kroutil A, Ž ák F, Mistr A & Turánek J 2005 High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochemical Pharmacology 69 373-383. (doi:10.1016/j.bcp.2004.09.005)
47. Krause-Heuer AM, Wheate NJ, Tilby MJ, Pearson D, Ottley CJ & Aldrich- Wright JR 2008 Substituted b-cyclodextrin and calix[4]arene as encapsulatory vehicles for platinum(II)-based DNA intercalators. Inorganic Chemistry 47 6880-6888. (doi:10.1021/ic800467c)
48. Lao Y-H, Phua KKL & Leong KW 2015 Aptamer nanomedicine for cancer therapeutics: Barriers and potential for translation. ACS Nano 9 2235-2254. (doi:10.1021/nn507494p)
49. Li J, Pant A, Chin CF, Ang WH, Menard-Moyon C, Nayak TR, Gibson D, Ramaprabhu S, Panczyk T, Bianco A & Pastorin G 2014 In vivo biodistribution of platinum-based drugs encapsulated into multiwalled carbon nanotubes. Nanomedicine : Nanotechnology, Biology, and Medicine 10 1465-1475. (doi:10.1016/j.nano.2014.01.004)
50. Liu K-J, Guan Z-Z, Liang Y, Yang X-Q, Peng J, Huang H, Qing-Xiang S, Meng-Zhao W, Zhu Y-Z, Wu C-P et al. 2014 A double-blind, randomized phase II study of dicycloplatin plus placlitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-smallcell lung cancer. Archives of Medical Science 10 717-724. (doi:10.5114/aoms.2014.44862)
51. Luo L-Z, Jin H-W & Huang H-Q 2012 Transferrin-cisplatin specifically deliver cisplatin to HepG2 cells in vitro and enhance cisplatin cytotoxicity. Journal of Proteomics 77 237-250. (doi:10.1016/j.jprot.2012.08.023)
52. Ma H, Liu J, Ali MM, Mahmood MAI, Labanieh L, Lu M, Iqbal SM, Zhang Q, Zhao W & Wan Y 2015 Nuclei acid aptamers in cancer research, diagnosis and therapy. Chemical Society Reviews 44 1240-1256. (doi:10.1039/C4CS00357H)
53. Mahdavifar Z & Moridzadeh R 2014 Theoretical prediction of encapsulation and adorption of platinum-anticancer drugs into single walled boron nitride and carbon nanotubes. Journal of Inclusion Phenomena and Macrocyclic Chemistry 79 443-457. (doi:10.1007/s10847-013-0367-1)
54. Mai J, Song S, Rui M, Liu D, Ding Q, Peng J & Xu Y 2009 A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells. Journal of Controlled Release 139 174-181. (doi:10.1016/j.jconrel.2009.06.024)
55. Massaguer A, Gonzalez-Canto A, Escribano E, Barrabes S, Artigas G, Moreno V&Marchan V2015 Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides. Dalton Transactions 44 202-212. (doi:10.1039/C4DT02710H)
56. McGinely NL, Plumb JA & Wheate NJ 2013 DNA-b, based aptamer fails as a simultaneous cancer targeting agent and drug delivery vehicle for a phenanthroline-based platinum(II) complex,. Journal of Inorganic Biochemistry 128 124-130. (doi:10.1016/j.jinorgbio.2013.07.021)
57. Mejri A, Vardanega D, Tangour B, Gharbi T & Picaud F 2015 Encapsulation into carbon nanotubes and release of anticancer cisplatin drug molecule. Journal of Physical Chemistry. B 119 604-611. (doi:10.1021/jp5102384)
58. Moghaddam S, Yang C, Rekharsky M, Ko YH, Kim K, Inoue Y & Gilson MK 2011 New ultrahigh affinity host-guest complexes of cucurbit[7]uril with bicyclo[2.2.2]octane and adamantane guests: thermodynamic analysis and evaluation of M2 affinity calculations. Journal of the American Chemical Society 133 3570-3581. (doi:10.1021/ja109904u)
59. Moghaddas S, Majmudar P, Marin R, Dezvareh H, Qi C, Soans E & Bose RN 2012 Phosphaplatins, next generation platinum antitumor agents: a paradigm shift in designing and defining molecular targets. Inorganica Chimica Acta 393 173-181. (doi:10.1016/j.ica.2012.05.040)
60. Nguyen H, Nguyen NH, Tran NQ & Nguyen CK 2015 Improvedmethod for preparing cisplatin-dendrimer nanocomplex and its behavior against NCi-H460 lung cancer cell. Journal of Nanoscience and Nanotechnology 15 4106-4110. (doi:10.1166/jnn.2015.9808)
61. Osman AA, Neskey DM, Katsonis P, Patel AA, Ward AM, Hsu T-K, Hicks SC, McDonald TO, Ow TJ, Alves MO et al. 2015 Evoluntionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients. Cancer Research 75 1205-1215. (doi:10.1158/0008-5472.CAN-14-2729)
62. Oun R, Floriano RS, Isaacs L, Rowan EG & Wheate NJ 2014 The ex vivo neurotoxic, myotoxic and cardiotoxic activity of cucurbituril-based macrocyclic drug delivery vehicles. Toxicology Research 3 447-455.(doi:10.1039/C4TX00082J)
63. Panczyk T, Jagusiak A, Pastorin G, Ang WH & Narkiewicz-Michalek J 2013 Molecular dynamics study of cisplatin release from carbon nanotubes capped by magnetic nanoparticles. journal of Physical Chemistry. C, Nanomaterials and Interfaces 117 17327-17336. (doi:10.1021/jp405593u)
64. Park GY, Wilson JJ, Song Y & Lippard SJ 2012 Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. PNAS 109 11987-11992. (doi:10.1073/pnas.1207670109)
65. Pisani MJ, Wheate NJ, Keene FR, Aldrich-Wright JR & Collins JG 2009 Anionic PAMAM dendrimers as drug delivery vehicles for transition metal-based anticancer drugsAnionic PAMAM. Journal of Inorganic Biochemistry 103 373-380. (doi:10.1016/j.jinorgbio.2008.11.014)
66. Plumb JA, Venugopal B, Oun R, Gomez-Roman N, Kawazoe Y, Venkataramanan NS & Wheate NJ 2012 Cucurbit[7]uril encapsulated cisplatin overcomes cisplatin resistance via a pharmacokinetic effect. Metallomics 4 561-567. (doi:10.1039/c2mt20054f)
67. Poland CA, Duffin R, Kinloch I, Maynard A, Wallace WAH, Seaton A, Stone V, Brown S, MacNee W & Donaldson K 2008 Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nature Nanotechnology 3 423-428. (doi:10.1038/nnano.2008.111)
68. Prashar D, Shi Y, Bandyopadhyay D, Dabrowiak JC & Luk Y-Y 2011 Adamantane-platinum conjugate hosted in b-cyclodextrin: enhancing transport and cytotoxicity by noncovalent modification. Bioorganic & Medicinal Chemistry 21 7421-7425. (doi:10.1016/j.bmcl.2011.10.006)
69. Pulskamp K, Woerle-Knirsch JM, Hennrich F, Kern K & Krug HF 2007 Human lung epithelial cells show biphasic oxidative burst after single walled carbon nanotube contact. Carbon 45 2241-2249. (doi:10.1016/j.carbon.2007.06.054)
70. Pur FN & Dilmaghani KA 2014 Calixplatin: novel potential anticancer agent based on the platinum complex with functionalized calixarene. Journal of Coordination Chemistry 67 440-448. (doi:10.1080/00958972.2014.890718)
71. Rolland O, Turrin C-O, Caminade A-M & Majoral J-P 2009 Dendrimers and nanomedicine: multivalency in action. New Journal of Chemistry 33 1793-1980. (doi:10.1039/b901054h)
72. Rowe RC, Sheskey PJ, Look WG & Fenton ME 2012 Handbook of Pharmaceutical Excipients, 7th edn. London, UK: Pharmaceutical Press.
73. Ruggiero A, Trombatore G, Triarico S, Arena R, Ferrara P, Scalzone M, Pierri F & Riccardi R 2013 Platinum compounds in children with cancer: toxicity and clinical management. Anti-Cancer Drugs 24 1007-1019. (doi:10.1097/CAD.0b013e3283650bda)
74. Sanchez-Paradinas S, Perez-Andres M, Almendral-Parra MJ, Rodriguez- Fernandez E, Millan A, Palacio F, Orfao A, Criado JJ & Fuentes M 2014 Enhanced cytotoxic activity of bile acid cisplatin derivatives by conjugation with gold nanoparticles. Journal of Inorganic Biochemistry 131 8-11. (doi:10.1016/j.jinorgbio.2013.10.021)
75. Sava G & Dyson PJ 2006 Metal-based antitumour drugs in the post genomic era. Dalton Transactions 16 1929-1933. (doi:10.1039/B601840H)
76. Seif M, Impelido ML, Apps MG & Wheate NJ 2014 Topical cream-based dosage forms of the macrocyclic drug delivery vehicle cucurbit[6]uril. PLoS ONE 9 e85361. (doi:10.1371/journal.pone.0085361)
77. Shangguan D, Tang Z, Mallikaratchy P, Xiao Z & TanW2007 Optimization and modifications of aptamer selected from live cancer cell lines. Chembiochem 8 603-606. (doi:10.1002/cbic.200600532)
78. Shi Y, Goodisman J & Dabrowiak JC 2013 Cyclodextrin capped gold nanoparticles as a delivery vehicle for a prodrug of cisplatin. Inorganic Chemistry 52 9418-9426. (doi:10.1021/ic400989v)
79. Stathopoulos GP & Boulikas T 2012 Lipoplatin formulation review article. Journal of Drug Delivery article 581363. (doi:10.1155/2012/581363)
80. Tekade RK, Kumar PV & Jain NK 2009 Dendrimers in oncology: an expanding horizon. Chemical Reviews 109 49-87. (doi:10.1021/cr068212n)
81. Torchilin V 2011 Tumour delivery of macromolecular drugs based on the EPR effect. Advanced Drug Delivery Reviews 63 131-135. (doi:10.1016/j.addr.2010.03.011)
82. Veal GJ, Dias E, Price E, Parry A, Errington J, Hale J, Pearson ADJ, Boddy AV, Newell DR & Tilby MJ 2001 Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Clinical Cancer Research 7 2205-2212.
83. Waalboer DCJ, Muns JA, Sijbrandi NJ, Schasfoort RBM, Haselberg R, Somsen GW, Houthoff H-J & van Dongen GAMS 2015 Platinum (II) as a bifunctional linker in antibody-drug conjugate formation: coupling of a 4-nitrobenzo-2-oxa-1,3diazole fluorophore to trastuzumab as a modelPlatinum II),. ChemMedChem 10 797-803. (doi:10.1002/cmdc.201402496)
84. Wagstaff AJ, Brown SD, Holden MR, Craig GE, Plumb JA, Brown RE, Schreiter N, Chrzanowski W& Wheate NJ 2012 Cisplatin drug delivery using gold-coated iron oxide nanoparticles for enhanced tumour targeting with external magnetic fields. Inorganica Chimica Acta 393 328-333. (doi:10.1016/j.ica.2012.05.012)
85. Walker S, Kaur R, McInnes FJ & Wheate NJ 2010 Synthesis, processing and solid state excipient interactions of cucurbit[6]uril and its formulation into tablets for oral drug delivery. Molecular Pharmacology 7 2166-2172. (doi:10.1021/mp100191b)
86. Walker S, Oun R, McInnes FJ & Wheate NJ 2011 The potential of cucurbiturils in drug delivery. Israel Journal of Chemistry 51 616-624. (doi:10.1002/ijch.201100033)
87. Wexselblatt E & Gibson D 2012 What do we know about the reduction of Pt(IV) pro-drugs? Journal of Inorganic Biochemistry 117 220-229. (doi:10.1016/j.jinorgbio.2012.06.013)
88. Wheate NJ 2008 Improving platinum(II)-based anticancer drug delivery using cucurbit[n]urils. Journal of Inorganic Biochemistry 102 2060-2066. (doi:10.1016/j.jinorgbio.2008.06.005)
89. Wheate NJ, Taleb RI, Krause-Heuer AM, Cook RL, Wang S, Higgins VJ & Aldrich-Wright JR 2007 Novel platinum(II)-based anticancer complexes and molecular hosts as their drug delivery vehicles. Dalton Transactions 43 5055-5064. (doi:10.1039/b704973k)
90. Wheate NJ, Abbott GM, Tate RJ, Clements CJ, Edrada-Ebel R & Johnston BF 2009 Side-on binding of p-sulphonatocalix[4]arene to the dinuclear platinum complex trans-[{PtCl(NH3)2)}2u-dpzm]2+ and its implications for anticancer drug delivery. Journal of Inorganic Biochemistry 103 448-454. (doi:10.1016/j.jinorgbio.2008.12.011)
91. Wheate NJ, Walker S, Craig GE & Oun R 2010 The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Transactions 39 8113-8127. (doi:10.1039/c0dt00292e)
92. Xia W & Low PS 2010 Folate-targeted therapies for cancer. Journal of Medicinal Chemistry 53 6811-6824. (doi:10.1021/jm100509v)
93. Xu H, Robinson GW, Huang J, Lim JY-S, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S et al. 2015 Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nature Genetics 47 263-266. (doi:10.1038/ng.3217)
94. Yu JJ, Yang X, Song Q, Mueller MD & Remick SC 2014 Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of chinese preclinical and clincal profile and emerging mechanistic studies. Anticancer Research 34 455-464.
95. Zalba S & Garrido MJ 2013 Liposomes, a promising strategy for clinical application of platinum derivatives. Expert Opinion on Drug Delivery 10 829-844. (doi:10.1517/17425247.2013.778240)
96. Zhao Y, Bali MS, Cullinane C, Day AI & Collins JG 2009 Synthesis, cytotoxicity and cucurbituril binding of triamine linked dinuclear platinum complexes. Dalton Transactions 26 5190-5198. (doi:10.1039/b905112k)
97. Zhao M-X, Zhao M, Zeng E-Z, Li Y, Li J-M, Cao Q, Tan C-P, Ji L-N & Mao Z-W 2014 Enchanced anti-cancer efficacy to cancer cells by doxorubicin loaded water-soluble amino acid-modified b-cyclodextrin platinum complexes. Journal of Inorganic Biochemistry 137 31-39. (doi:10.1016/j.jinorgbio.2014.03.012)